Bicara Therapeutics Inc. insider trading

BCAXNASDAQ

$17.63-0.57 (-3.13%)as of Oct 2, 2026

“Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.” — Peter Lynch

Insider Trading vs Stock Price data

Showing the 1Y range: Oct 2, 2025 to Oct 2, 2026. Price (+5.5%). 0 insider transactions plotted in this window as 0 markers; nearby trades of the same kind are grouped.

Transactions plotted on the price chart
Date	Category	Person	Role	Action	Amount	Change in holding

Open market purchase

Open market sell

Marker size reflects transaction size.

Net dollar flow · Buy / Sell balance

Premium

Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Unlock quarterly net flow

Key players

CMClaire MazumdarChief Executive Officer0.5473%of company
RCRyan CohlheppPresident, COO & Interim CEO0.2745%of company
IHIvan HyepChief Financial Officer0.1962%of company
DRDavid RabenChief Medical Officer0.0835%of company
LMLara MeisnerChief Legal Officer0.00%of company
RCRa Capital Management, L.P.DirectorNot reportedof company

AI Activity Analysis

Premium

Coming soonAI reads of insider activity will appear here for Premium accounts.

Insider activity

Fromto

Company	Insider / role	Action	ΔOwn	Avg price	Amount
BCAX	Ryan CohlheppPresident and COO	Open market sell$15.5K	-0.3%	$29.00	$15.5K	Jul 9, 2026	Jul 10, 2026
BCAX	Ra Capital Management, L.P.Director	Open market purchase$4.8M	+7.0%	$16.00	$4.8M	Feb 26, 2026	Mar 2, 2026
BCAX	Ryan CohlheppPresident and COO	Open market sell$69.3K	-1.8%	$18.10	$69.3K	Jan 22, 2026	Jan 26, 2026
BCAX	Ryan CohlheppPresident and COO	Open market sell$2.68K	-0.1%	$18.02	$2.68K	Jan 15, 2026	Jan 20, 2026

End of history · 4 transactions